Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanqi Xueshangning San is a traditional Chinese medicine (TCM) oral powder developed and manufactured by Guilin Sanjin Pharmaceutical. The formulation is primarily composed of *Panax notoginseng* (Sanqi) and other herbal components such as Borneol. It is clinically utilized for its hemostatic, anti-inflammatory, and analgesic properties, specifically targeting traumatic injuries, internal and external bleeding, and swelling associated with blood stasis. The therapeutic effect is attributed to the synergistic action of its constituents, which promote blood circulation to resolve stasis while simultaneously facilitating the cessation of bleeding without inducing further thrombotic complications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sanqi xueshangning san.